Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

Pfizer proudly flaunts its “World’s Most Ethical Companies” award, but this honor is a pay-to-play scheme, not a genuine ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Pfizer remained flat while the S&P 500 dropped ... Eliquis saw 10% global growth, while Nurtec recorded a 36% increase in global revenue and maintained a 49% market share in the oral CGRP class ...

Pfizer’s non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those ...

However, the big drugmaker also has multiple strong growth drivers, notably including cancer drugs Adcetris and Padcev and migraine therapy Nurtec ODT. There's another reason to buy Pfizer stock ...